Related Experiment Videos
Protein C pathway in infants and children
Jari Petäjä1, Marilyn J Manco-Johnson
1Department of Pediatrics, Helsinki University Central Hospital, Jorvi Hospital, Helsinki, Finland. jari.petaja@hus.fi
Seminars in Thrombosis and Hemostasis
|October 1, 2003
Summary
Congenital defects in the protein C pathway increase the risk of blood clots in children. Acquired disturbances during sepsis also impact this critical anticoagulant system.
Area of Science:
- Biochemistry
- Hematology
- Pediatrics
Background:
- The protein C pathway is a key physiological anticoagulant system.
- Congenital defects like protein C/S deficiencies and Factor V Leiden are linked to pediatric venous thromboembolism.
- This pathway regulates coagulation and inflammation in sepsis and disseminated intravascular coagulation.
Purpose of the Study:
- To review the physiology of the protein C pathway, focusing on pediatric aspects.
- To discuss the clinical implications of protein C pathway defects in pediatric venous thromboembolism.
- To examine acquired disturbances of the protein C pathway during sepsis.
Main Methods:
- Literature review of the protein C pathway's physiology.
- Analysis of congenital defects and their association with pediatric venous thromboembolism.
- Discussion of acquired protein C pathway disturbances in sepsis.
Main Results:
- Heterozygous deficiencies of protein C and S, and Factor V Leiden, are significant risk factors for pediatric venous thromboembolic disease.
- The protein C pathway plays a crucial role in managing coagulation and inflammation during sepsis.
- Acquired defects in this pathway are relevant in critically ill children with sepsis.
Conclusions:
- Understanding the protein C pathway is vital for diagnosing and managing thrombotic events in children.
- Defects in this system have profound implications for both inherited thrombophilia and acquired conditions like sepsis.
- Further research into pediatric-specific aspects of the protein C pathway is warranted.